Masera and colleagues recently published case reports of lens opacities in three patients with b-thalassemia major that were suggested to be associated with exposure to deferasirox (ICL670, Exjade); the opacities developed 7, 16 and 26 months after initiating deferasirox therapy. These three patients are from a total of 12 being followed by the authors at their institution. This reported incide...

We read with interest the article by Pepe et al. wherein the authors retrospectively compared cardiac iron burden measured by T2* magnetic resonance imaging (MRI) in three groups of beta-thalassemia major patients treated with desferrioxamine, deferiprone, or deferasirox monotherapy for more than one year. The mean global heart T2* value was significantly higher in the deferiprone compared to t...